Periostin expression and characters of human adipose tissue-derived mesenchymal stromal cells were aberrantly affected by
AD-MSCs
DNA index (DI)
cell proliferation assay
colony forming unit (CFU)
periostin gene
Journal
Stem cell investigation
ISSN: 2306-9759
Titre abrégé: Stem Cell Investig
Pays: China
ID NLM: 101672113
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
11
2018
accepted:
30
07
2019
entrez:
18
10
2019
pubmed:
18
10
2019
medline:
18
10
2019
Statut:
epublish
Résumé
Human adipose tissue-derived mesenchymal stromal cells (AD-MSCs) have been under focus in regenerative medicine since their discovery as a suitable source of MSCs. AD-MSCs are heterogeneous cells and exhibit variations in population doubling time, morphology and proliferative capacity. This study investigated if human AD-MSCs are developing, during This study monitored AD-MSCs during their The proliferation capacity and colony forming unit were decreased after passage 6 and the population doubling time was increased. Flow cytometric analysis revealed that newly cultivated population strongly expressed MSCs markers, furthermore, reduction of CD105 expression appeared in passage 5 onwards, the later was associated with significant increase in expression of CD34 (a hematopoietic cell marker). Also, reduction of CD73 and CD90 expression was observed from passage 8. Furthermore, during the first six passages, periostin expression was significantly unchanged, with significant upregulation in late passages. Long-term cultivation of human AD-MSCs changed their characters in an aberrant way and the first four passages might be the most appropriate passages for therapy. More investigation and understanding of these variations are needed to help in standardizing the expansion of MSCs-based therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Human adipose tissue-derived mesenchymal stromal cells (AD-MSCs) have been under focus in regenerative medicine since their discovery as a suitable source of MSCs. AD-MSCs are heterogeneous cells and exhibit variations in population doubling time, morphology and proliferative capacity. This study investigated if human AD-MSCs are developing, during
METHODS
METHODS
This study monitored AD-MSCs during their
RESULTS
RESULTS
The proliferation capacity and colony forming unit were decreased after passage 6 and the population doubling time was increased. Flow cytometric analysis revealed that newly cultivated population strongly expressed MSCs markers, furthermore, reduction of CD105 expression appeared in passage 5 onwards, the later was associated with significant increase in expression of CD34 (a hematopoietic cell marker). Also, reduction of CD73 and CD90 expression was observed from passage 8. Furthermore, during the first six passages, periostin expression was significantly unchanged, with significant upregulation in late passages.
CONCLUSIONS
CONCLUSIONS
Long-term cultivation of human AD-MSCs changed their characters in an aberrant way and the first four passages might be the most appropriate passages for therapy. More investigation and understanding of these variations are needed to help in standardizing the expansion of MSCs-based therapies.
Identifiants
pubmed: 31620480
doi: 10.21037/sci.2019.08.09
pii: sci-06-2019.08.09
pmc: PMC6789196
doi:
Types de publication
Journal Article
Langues
eng
Pagination
33Informations de copyright
2019 Stem Cell Investigation. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Cytotherapy. 2005;7(6):509-19
pubmed: 16306013
Mol Cell Biol. 2004 May;24(9):3992-4003
pubmed: 15082792
Cell Biol Int. 2008 Apr;32(4):384-93
pubmed: 18262807
J Biol Chem. 2008 Jun 27;283(26):17991-8001
pubmed: 18450759
Cytotherapy. 2013 Nov;15(11):1323-39
pubmed: 23992670
Am J Sports Med. 2010 Jun;38(6):1110-6
pubmed: 20392971
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Ageing Res Rev. 2006 Feb;5(1):91-116
pubmed: 16310414
Anat Cell Biol. 2013 Jun;46(2):113-21
pubmed: 23869258
Cancer Res. 2005 Apr 15;65(8):3035-9
pubmed: 15833829
Cytotherapy. 2013 Jul;15(7):753-9
pubmed: 23602595
Oncotarget. 2016 Mar 8;7(10):10788-802
pubmed: 26910916
PLoS One. 2008 May 21;3(5):e2213
pubmed: 18493317
Stem Cells Dev. 2015 Jan 1;24(1):77-92
pubmed: 25019198
Int J Stem Cells. 2014 Nov;7(2):135-42
pubmed: 25473451
Cancer Sci. 2013 May;104(5):525-30
pubmed: 23360516
Cell Reprogram. 2013 Feb;15(1):80-91
pubmed: 23298400
Cancer Res. 2006 Jul 15;66(14):6928-35
pubmed: 16849536
J Biol Chem. 2014 Mar 21;289(12):8545-61
pubmed: 24469446
Cell Reprogram. 2014 Aug;16(4):298-305
pubmed: 25068631
Cloning Stem Cells. 2009 Sep;11(3):445-52
pubmed: 19594392
Stem Cells Int. 2012;2012:652034
pubmed: 22685475
Cell Reprogram. 2012 Aug;14(4):342-52
pubmed: 22775457
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Osteoporos Int. 2012 Apr;23(4):1199-212
pubmed: 22310955
PLoS One. 2013 Aug 29;8(8):e72962
pubmed: 24009721
J Cell Biochem. 2001;82(4):583-90
pubmed: 11500936
Cell Reprogram. 2012 Oct;14(5):448-55
pubmed: 22908943
Aging (Albany NY). 2010 Apr;2(4):224-30
pubmed: 20453259
Am J Obstet Gynecol. 1997 Jun;176(6):1319-26; discussion 1326-7
pubmed: 9215191
Aging Cell. 2010 Feb;9(1):54-63
pubmed: 19895632
Cancer Sci. 2018 Mar;109(3):688-698
pubmed: 29284199
Curr Issues Mol Biol. 2001 Jul;3(3):67-70
pubmed: 11488413
Stem Cells Dev. 2015 Mar 15;24(6):677-85
pubmed: 25517941
Cell Reprogram. 2013 Oct;15(5):471-80
pubmed: 24073944
Theriogenology. 2007 Jan 1;67(1):105-11
pubmed: 17055565
Stem Cells Transl Med. 2013 Oct;2(10):808-17
pubmed: 24018794
Stem Cells Int. 2015;2015:146051
pubmed: 25688272
Cytotherapy. 2013 Nov;15(11):1307-8
pubmed: 24094485
Cell Reprogram. 2013 Oct;15(5):425-34
pubmed: 23961765